The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Https://youtu.be/E1dA3Rv3Rek?si=qheksq888uTJuGOy
9 to 14 minutes they talk about obd and the problems
Oxford BioDynamics Plc (OBD.L) has experienced significant price movements over the past year, with its price ranging from 9.00 GBp to 52.00 GBp. Such volatility suggests the stock has been subject to various market forces and potentially internal company developments. The company's market cap is 19.583M, and it has recently closed at 9.68 GBp, indicating a 1.47% increase. Despite the recent gains, the stock's performance has been challenging, with a year-to-date decline of -64.15% and a five-year decline of -93.66%.
This deep analysis considers the company's operational field in biotechnology and recent strategic agreements, such as with Bupa for the EpiSwitch® CiRT for cancer patients and the U.S. launch of its EpiSwitch® Prostate Screening Blood Test. These initiatives reflect Oxford BioDynamics' efforts to expand its market presence and revenue streams. However, the financials show a company in a delicate phase, with negative EPS (TTM) of -0.07 and no PE Ratio, reflecting the current unprofitability.
Considering these factors, the potential future performance of Oxford BioDynamics' stock could hinge on the successful commercialization of its biotechnological innovations and the broader market's reception of these advances. If the company can leverage its strategic initiatives to generate sustainable revenue growth, there could be potential for stock price recovery. However, the current financial health and the stock's significant historical decline suggest cautious optimism. Investors might look for signs of sustained financial improvement and market acceptance of its products before a strong positive momentum can be established.
---
I know everyone is losing faith, me included, because the company refuses to communicate with investors
On the upside Bupa heavily advertises in this country and if they use Obd and are happy with the results being the most accurate on the market the amount of customers will snowball and Obd's fortunes will turn around
The same can be said for America where they are using Medicare and Mediaid
The daily mail is running a story today about Stephen Fry having to wait along time for treatment for prostate cancer
In the public comments about the story one reader has commented
2 years 6 months wait for prostate cancer treatment.
MRI in Feb 2022 showed prostate cancer had spread to the pelvis(bone cancer) radiologist 'missed it' I asked for another scan later to see if the cancer had spread and then had to wait 5 weeks for the results, luckily it hadn't
NHS seems to be relying on MRI scans where a blood test would confirm results earlier and not miss vital things
Alot of missed opportunities for obd with their current technology, I hope they turn this around
Prostate Cancer UK are running a story in the Daily Mail today
Tests and Treatment
Tests for prostrate Cancer are haphazard, with accurate tools only just beginning to emerge
There is no national prostrate screening programme as for years the tests have been too inaccurate
Doctors struggle to distinguish between aggressive and less serious tumours, making it hard to decide on treatment
Men over 50 are eligible for a PSA blood test which gives doctors a rough idea of whether the patient is at risk
But it is unreliable. Patients who get a positive result are usually given a biopsy which is also not fool-proof
Scientists are unsure as to what causes prostrate cancer, but age, obesity and a lack of exercise are known risks
i can't understand why this company let's the share price go to ****, no communication no response
just put something out, anything, so we know your still alive
In Feb 23 when they announced 94% accuracy in the pse test, the national media ran the story and obd put a message on their website that they were inundated with requests about the test
So a national advertising campaign here or America would get the ball moving
Its still a valuable product but hasn't been marketed properly, they've tried to juggle all the balls at once and took their focus off the main product which is selling
Once this has been sorted the share price will rise as the sell off has been completely overdone
Sell-off is completely overdone
The only thing they've failed on is marketing
Product is valuable and life saving
Hopefully this is the kick up the backside management need to refocus their efforts
How this share price is still languishing in the 30p range is beyond me
On Wednesday it will be only positive news, management have worked hard to get this product to market, now the medical world needs to take notice
The average age of the directors is 60+, this is their time now, can't go back and start again If this doesn't take off
Come on obd
Every bit of news is good news, knowing now that legislation in America will compel health institutions to use biomarkers technology is almost like a licence to print money, obd is in the right place at the right time
This is great news, another piece of the puzzle coming into play to make obd a success
Boom
America's got the numbers OBD has the product get ready for takeoff
27 Sept 2023
Analysts at Shore Capital said there are approximately 47 million men in the relevant 50-80 age range in the key US market and 25 million PSA tests per year and a further 10 million men in the UK
The medical need for an improved test is clear
The Prostrate Cancer Foundation is based in the USA 🇺🇸
Howard Shore head of Shore Capital, holders and advisors to obd, is also on the board of The Prostate Cancer Foundation
Roche just bought Carmot Therapeutics for $3.1 billion, could be a good year for mergers and acquisitions
Obd shares peaked at £2.79 October 2017 and they didn't have anything like they've got today
After doing some extensive research on the Internet analysts predict a price between 48p and £1.08 during the next 3 months, happy days
If they just release an rns that Jon Burrows has been celebrating all weekend, the sp will perk up
This ship is on course for America, surprised you jumped overboard seeing as you was a great advocate for the product
Final results due in January, sales will have increased and maybe a partnership signed, the sp will reflect this
Morning I think obd will be involved the pse test is too accurate to ignore
The first thing they do when your sick now is send you for blood tests, can't see this being any different